Nocturnal hypoxia as an additional factor of functional kidney damage in patients with obstructive sleep apnoea syndrome Source: Annual Congress 2008 - Weight control and comorbidity in obstructive sleep apnoea Year: 2008
S100B protein: A useful marker in obstructive sleep apnea syndrome Source: Annual Congress 2012 - Clinical predictors of OSA, adherence to CPAP and psychology Year: 2012
Correlations between severity of nocturnal hypoxemia and level of Galectin-3 in obstructive sleep apnea patients Source: International Congress 2019 – Consequences of sleep-disordered breathing from molecular and clinical points of view Year: 2019
Roles of periostin in patients with severe obstructive sleep apnea Source: International Congress 2017 – New pathophysiological insights: intermittent hypoxia, cardiopulmonary function and biomarkers Year: 2017
Cortisol metabolism in obstructive sleep apnea (OSA) Source: Eur Respir J 2002; 20: Suppl. 38, 215s Year: 2002
The role of angiogenesis in obstructive sleep apnea (OSA) Source: Eur Respir J 2005; 26: Suppl. 49, 357s Year: 2005
Association between metabolic disturbances and inflammatory markers in obstructive sleep apnea (OSAS) patients Source: Annual Congress 2008 - Metabolic syndrome and systemic inflammation in obstructive sleep apnoea Year: 2008
Pathophysiological consequences of obstructive sleep apnoea Source: Annual Congress 2006 - Obstructive sleep apnoea and cardiovascular diseases Year: 2006
Increased rates of obstructive sleep apnea (OSA) in COVID-19-patients Source: Virtual Congress 2021 – Sleep across the lifespan in the new era of COVID - 19 Year: 2021
Acetazolamide improves central sleep apnea in patients with obstructive sleep apnea syndrome at altitude Source: Annual Congress 2009 - Assessment and therapeutical interventions in obstructive sleep apnoea Year: 2009
Catecholamine secretion in obstructive sleep apnoea (OSA) Source: Eur Respir J 2005; 26: Suppl. 49, 38s Year: 2005
Increased arterial stiffness in patients with obstructive sleep apnea: clinical implication Source: Sleep and Breathing Conference 2021 Year: 2021
Leptin in obstructive sleep apnea Source: Eur Respir J 2001; 18: Suppl. 33, 333s Year: 2001
Glucose metabolism abnormalities in obstructive sleep apnoea (OSA) patients Source: Annual Congress 2012 - Metabolic and cardiovascular consequences of OSA I Year: 2012
Daytime ventilatory instability in obese patients with obstructive sleep apnea (OSA) Source: Eur Respir J 2001; 18: Suppl. 33, 334s Year: 2001
The role of inflammatory biomarkers in obstructive sleep apnea syndrome Source: International Congress 2018 – Sleep-disordered breathing: biomarkers and genetics and the role of hypoxia, insomnia, movement disorders and sleep quality Year: 2018
Predictors of hypercapnia in obstructive sleep apnoea (OSA) Source: Annual Congress 2010 - Lung disease and mountain sickness: the importance of ventilatory control Year: 2010
The effect of CPAP treatment on Galectin-3 level in patients with severe obstructive sleep apnea Source: International Congress 2018 – Cardiovascular and metabolic consequences of sleep-disordered breathing Year: 2018
Signalling pathways in intermittent hypoxia and in obstructive sleep apnoea (OSA) Source: Annual Congress 2007 - Cardiovascular and metabolic consequences of obstructive sleep apnoea: early changes, biomarkers and impact of treatment Year: 2007
Comparison of plasma NT-proBNP level in overlap syndrome (obstructive sleep apnoea + chronic obstructive pulmonary disease) and obstructive sleep apnoea (OSA) Source: Annual Congress 2008 - Control of breathing and respiratory disorders during sleep Year: 2008